SCHEMBL3203400

SCHEMBL3203400

CNCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2cccnc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.59
HTR6 P50406 14/20 0.58
HTR2C P28335 2/20 0.58
HTR7 P34969 2/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2A6 P11509 1/20 0.58
HTR2B P41595 1/20 0.58
ADRB2 P07550 1/20 0.55
CHRM2 P08172 1/20 0.55
ADRA2A P08913 1/20 0.55
S1PR1 P21453 1/20 0.55
C5AR1 P21730 1/20 0.55
SLC6A2 P23975 1/20 0.55
FPR3 P25089 1/20 0.55
HTR1D P28221 1/20 0.55
HTR1B P28222 1/20 0.55
HTR2A P28223 1/20 0.55
GPR183 P32249 1/20 0.55
ADRA1A P35348 1/20 0.55
HRH1 P35367 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3202434 0.88 HTR6 (0.75) METHTR6HTR2CHTR7CYP3A4
SCHEMBL3202014 0.88 MET (0.59) METHTR6HTR2CHTR7CYP3A4
SCHEMBL5738575 0.86 HTR6 (0.78) METHTR6HTR2CHTR7CYP3A4
SCHEMBL3210064 0.84 MET (0.57) METHTR6HTR2CHTR7CYP3A4
SCHEMBL4013416 0.77 HTR6 (0.74) METHTR6HTR2CHTR7CYP3A4
SCHEMBL5739373 0.75 HTR6 (0.74) METHTR6HTR2CHTR7CYP3A4
SCHEMBL5738587 0.74 HTR6 (0.73) METHTR6HTR2CHTR7CYP3A4
SCHEMBL3215633 0.74 HTR6 (0.68) METHTR6HTR7HTR1DHTR1B
SCHEMBL3889994 0.74 HTR6 (0.55) METHTR6HTR2CHTR7CYP3A4
SCHEMBL801436 0.74 HTR6 (1.00) METHTR6HTR2CHTR7CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1A, HTR5A MET 1008/4885HTR6 1/4885HTR2C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.